Quote | CureVac N.V. (NASDAQ:CVAC)
Last: | $3.34 |
---|---|
Change Percent: | -0.6% |
Open: | $3.35 |
Close: | $3.34 |
High: | $3.46 |
Low: | $3.28 |
Volume: | 670,907 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | CureVac N.V. (NASDAQ:CVAC)
2024-06-25 12:31:58 ET More on CSL CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL Divi...
2024-06-14 10:59:33 ET More on bird flu CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Virax surges amid bird flu concerns Bird flu death in Mexico linked to strain not seen in humans before Third human bird flu case found...
Message Board Posts | CureVac N.V. (NASDAQ:CVAC)
Subject | By | Source | When |
---|---|---|---|
$CVAC CureVac NV | mick | investorshub | 04/30/2023 10:27:40 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 7:10:09 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:33 PM |
$CVAC CureVac NV | mick | investorshub | 04/15/2023 2:57:32 PM |
$CVAC CureVac NV | mick | investorshub | 02/26/2023 11:52:14 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine ca...
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK Settlement wi...
CureVac N.V. (NASDAQ: CVAC) is one of today's top gainers. The company's shares have moved 23.1% on the day to $4.05. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing pr...